POZEN Inc. announced that Mark A. Glickman has been named Chief Commercial Officer of the company, a newly created position effective immediately, with the intention of becoming Chief Commercial Officer of Aralez Pharmaceuticals upon the completion of the pending merger between the company and Tribute. Eric L. Trachtenberg has been named Deputy General Counsel of the company, effective immediately, with the intention of becoming General Counsel of Aralez Pharmaceuticals upon the completion of the pending merger between the company and Tribute; and Jennifer L. Armstrong has been named Executive Vice President, Human Resources and Administration of the company, effective immediately, with the intention of becoming EVP Human Resources and Administration of Aralez Pharmaceuticals upon completion of the pending merger between the company and Tribute. Mr. Glickman has over 20 years of experience in pharmaceutical sales and operations, with expertise in a variety of fields including sales turnarounds, global product introductions and organizational expansions.

Mr. Glickman most recently served as Executive Vice President of Sales and Marketing for Auxilium Pharmaceuticals. Prior to that, he served as Vice President in the medical device division at Otsuka America Pharmaceutical Inc. At Otsuka, he helped to reinvigorate the company's sales and increase its business by 50% over two years, while also spearheading quality improvement initiatives and playing a critical role in new regulatory filings. Prior to Otsuka, Mr. Glickman served as Senior Vice President of Sales and Marketing at Oscient Pharmaceuticals Corp., during which time he completed a successful turnaround of the company's commercial strategy, driving a significant increase in sales.

Before joining Oscient, Mr. Glickman served as Vice President of Sales at Bayer Healthcare's Diabetes Care Division. From 2001 to 2007 he played a major role in helping to build the commercial organization at Kos Pharmaceuticals and held various positions including Director of Marketing, Regional Sales Director and Vice President of Sales. Mr. Glickman started his pharmaceutical career at Bristol-Myers Squibb where he was responsible for the marketing of cardiovascular products, including the blockbuster Plavix.

Mr. Trachtenberg has over 16 years of experience practicing law, including over ten years in the pharmaceutical industry. Mr. Trachtenberg most recently served as Deputy General Counsel at Auxilium Pharmaceuticals Inc., from 2012 through its acquisition by Endo Pharmaceuticals in February 2015. Prior to Auxilium, he was Vice President, General Counsel and Corporate Secretary of Enobia Pharma Inc. and managed all legal aspects of Enobia's sale to Alexion Pharmaceuticals.

Prior to that, Mr. Trachtenberg served as Vice President and Associate General Counsel of Sepracor Inc. and remained in that position with Sunovion Pharmaceuticals Inc. following the acquisition of Sepracor by Dainippon Sumitomo Pharma. Mr. Trachtenberg also held a Senior Counsel position at Kos Pharmaceuticals Inc. before its acquisition by Abbott. Mr. Trachtenberg began his career as an Associate at Blank Rome LLP.

Ms. Armstrong has over 15 years of experience in the Human Resources field, primarily in the biotech industry. Ms. Armstrong most recently served as Senior Vice President of Human Resources at Auxilium Pharmaceuticals Inc. Prior to that, she served at Senior Vice President of Human Resources and Corporate Communications at Genaera Corporation. During her decade long tenure at Genaera, Ms. Armstrong was responsible for all facets of Human Resources, including working directly with the Compensation Committee on executive and equity compensation strategies.

She also was responsible for investor and public relations while overseeing the IT and facilities functions.